Navigation Links
PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
Date:9/24/2008

reated with non-pegylated rBChE supports the conclusions of an earlier study (Mikler et al, 2007) that rBChE has potential utility as a post poisoning therapy. The investigators suggest that the data provide the first tangible evidence of the predicted mechanisms of post poisoning intervention with rBChE.

"The majority of our research to date for Protexia(R) has focused on studying its efficacy as a pre-exposure prophylactic. The promising preliminary data are particularly encouraging as they demonstrate that the non-pegylated rBChE may also be efficacious as a therapeutic for nerve agents. We plan to undertake further confirmatory work with Protexia(R) to build upon these exciting preliminary observations," said Mr. Wright.

Valortim(R) Findings Reported

In a poster entitled, "Efficacy of Intravenous Valortim(R), an Anti-toxin Monoclonal Antibody, in the Treatment of Inhalation Anthrax in the African Green Monkey Model," investigators at USAMRIID sought to refine the AGM as a therapeutic model by assessing the efficacy of an anti-toxin monoclonal antibody. In the study, 21 adult AGMs were exposed by aerosol to Ames anthrax spores and blood samples were collected every 4-8 hours beginning 24-hours post exposure to assess anthrax bacteremia and protective antigen in blood. Samples were analyzed for protective antigen via a rapid electrochemiluminescent immunoassay (ECL) and bacteremia was evaluated by 24-hour culture. In the study, 6 AGMs were treated with one intravenous dose of 10 mg/kg Valortim(R) when positive by ECL; a second cohort of 6 AGMs was treated with 2 intravenous doses of 10 mg/kg Valortim(R) (the first given when positive by ECL and the second dose administered 24 hours later), and a third cohort of 6 AGMs was treated with one intravenous dose of 20 mg/kg Valortim(R) when positive by ECL.

Results showed that 56% (10 of 18) of the Valortim(R)-treated animals survived while all saline-treated controls (3) succumbed to inhalati
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
(Date:7/13/2014)... The report “Micronutrient Market by ... (Chelated & Non Chelated), Application Mode (Soil, Foliar, ... and Forecast to 2018” defines and segments the ... forecasting of the global value and volume for ... restraining factors for the global agriculture micronutrients market ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... noninvasive optical imaging device developed at Cedars-Sinai can ... in the brain and are a classic sign ... investigators conducting a clinical trial in Australia. , ... in an oral presentation at the Alzheimer,s Association ... were invited by conference organizers to participate in ...
Breaking Medicine News(10 mins):Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
... 2 Covaris Incorporated today announced the introduction ... technology.Over the past few years, Covaris instruments have ... as a sample preparation step for next generation ... compatible with all next-gen sequencing platforms. This ...
... on Solidifying Interoperability Standards within HIT Solutions to ... April 2 Greenway Medical Technologies ... health record (EHR), practice management and interoperability solution ... and Management Systems Society (HIMSS) and Integrating the ...
... 2 Despite government efforts to address disparities in ... and Ethnic Health Disparities Initiative, there has been very ... death than Caucasians(1).The statistics are alarming:, ... are 1.6 times more likely to have diabetes than ...
... of alcohol-linked deaths are tied to bouts of excessive consumption, ... drinking in the United States is most common among whites, ... $50,000 or more a year, according to a study released ... or more drinks on one occasion. , The U.S. Centers ...
... of regrowing damaged cardiac tissue, experts say, , , THURSDAY, April ... found that the human heart continues to generate new cardiac ... cell production slows with age. , The finding, published ... open a new path for the treatment of heart diseases ...
... Patients with severe heart failure can be bridged to ... heart pump, according to a just-completed study of the ... reported at the 58th annual meeting of the American ... called a left ventricular assist device (LVAD), is the ...
Cached Medicine News:Health News:Covaris Introduces DNA Shearing Service 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 3Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 4Health News:Health Disparities Among Minority Populations Getting Worse 2Health News:Health Disparities Among Minority Populations Getting Worse 3Health News:Typical Binge Drinker Is Young White Male 2Health News:Human Heart Can Make New Cells 2Health News:Human Heart Can Make New Cells 3Health News:Artificial pump effectively backs up failing hearts 2Health News:Artificial pump effectively backs up failing hearts 3
... like all important missions, require ... you to your destination. The ... this dependability. So you can ... intervention and not have to ...
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
Tests for protan and deutan defects. Patients must identify numbers or patterns formed in a matrix of small colored dots varying in color and intensity. Two editions available: 38 plate for detailed ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
Medicine Products: